The International Journal of Neuropsychopharmacology
September 9, 2026
Friederike Holze, F Müller, Peter Gasser et al.
Abstract Background Anxiety disorders are a major health burden and current treatment options yield unsatisfactory results. Psychedelics, such as lysergic acid diethylamide (LSD) that act via agonism on serotonin 2A receptors, have recently been shown to be effective in the treatment of anxiety symptoms. Aims & Objectives Here, we determine the relationship between the acute experience and...
The International Journal of Neuropsychopharmacology
September 9, 2026
D McCulloch
Abstract Background LSD has recently entered phase 3 clinical trials for anxiety and depressive disorders, yet understanding of its mechanisms of action in the human brain remains incomplete. The serotonin 2A receptor (5-HT2AR) is the critical target for psychedelic effects, but no investigations to date have evaluated the relation between target engagement and systems-level brain function....
Proceedings of the National Academy of Sciences
September 8, 2026
Andrian G Basargin, Andras Domokosa, Joseph J. Hennessey et al.
Of the classic psychedelics, lysergic acid diethylamide (LSD) is perhaps the best-known, but its complex chemical architecture has limited synthetic investigations aimed at generating analogues with improved safety and efficacy profiles. Here, we systematically deconstruct the tetracyclic ergoline core of LSD to create 9 simplified ergoline analogues (i.e., ergologs) and evaluate them in...
The International Journal of Neuropsychopharmacology
September 1, 2026
Gabriella Gobbi
Abstract Background Lysergic acid diethylamide (LSD), a serotonergic psychedelic, has gained renewed interest for its potential anxiolytic effects in clinical trials. However, the neurobiological mechanisms underlying these effects remain poorly understood. Aims & Objectives The goal of this study is to understand the mechanism of action of LSD in animal models by using in vivo...
The International Journal of Neuropsychopharmacology
September 1, 2026
Amel Bouloufa, Sarah Delcourte, Renaud Rovera et al.
Abstract Background Recent clinical findings have highlighted the therapeutic potential of serotonergic psychedelics, including lysergic acid diethylamide (LSD), in the treatment of affective disorders. Despite these advances, the mechanisms driving their beneficial effects remain partially understood. Aims & Objectives This study sought to assess the prophylactic effects of LSD in rodent...
The International Journal of Neuropsychopharmacology
September 1, 2026
Abstract Background Depressive disorders affect approximately 280 million people worldwide, with many patients finding existing treatments ineffective or limited by adverse effects. Growing evidence from community microdosing reports suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing has shown particular promise...
Drug Testing and Analysis
August 27, 2026
Synthesis and Analytical Characterization of 1-(1,2-Dimethylcyclobutane-1-Carbonyl)-Lysergic Acid Diethylamide (1D-LSD) and Differentiation From 1-(Thiophene-2-Carbonyl)-LSD (1T-LSD).
Neuroscience of Consciousness
August 20, 2026
Low-dose lysergic acid diethylamide alters subjective visual perception but not visual contrast surround suppression.
bioRxiv
August 18, 2026
preprint
Tuning in together: LSD enhances inter-brain synchrony and felt connectedness in romantic couples
Med
August 14, 2026
Felix Müller, Anna M Becker, Christopher Böhlke et al.
In Basel, only a few hundred meters from where LSD was first synthesized, we tested LSD-assisted therapy for major depression in a randomized trial comparing two high doses with two low doses, each paired with supportive psychotherapy. This Backstory reflects on treating patients, long dosing days, and what remains uncertain.